Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Its Risk Factors

Total Page:16

File Type:pdf, Size:1020Kb

Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Its Risk Factors DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.631 Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and its Risk Factors RESEARCH ARTICLE Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Risk Factors for Fistula Development Zi-Xu Yuan1,2,3&, Teng-Hui Ma1&, Qing-Hua Zhong1, Huai-Ming Wang1, Xi-Hu Yu 1,3, Qi-Yuan Qin1, Li-Li Chu1, Lei Wang1,3*, Jian-Ping Wang1,3* Abstract Radiation proctitis is a common complication after radiotherapy for pelvic malignant tumors. This study was conducted to assess the efficacy of novel almagate enemas in hemorrhagic chronic radiation proctitis (CRP) and evaluate risk factors related to rectal deep ulcer or fistula secondary to CRP. All patients underwent a colonoscopy to confirm the diagnosis of CRP and symptoms were graded. Typical endoscopic and pathological images, risk factors, and quality of life were also recorded. A total of 59 patients were enrolled. Gynecological cancers composed 93.1% of the primary malignancies. Complete or obvious reduction of bleeding was observed in 90% (53/59) patients after almagate enema. The mean score of bleeding improved from 2.17 to 0.83 (P<0.001) after the enemas. The mean response time was 12 days. No adverse effects were found. Moreover, long-term successful rate in controlling bleeding was 69% and the quality of life was dramatically improved (P=0.001). The efficacy was equivalent to rectal sucralfate, but the almagate with its antacid properties acted more rapidly than sucralfate. Furthermore, we firstly found that moderate to severe anemia was the risk factor of CRP patients who developed rectal deep ulcer or fistulas P( = 0.015). We also found abnormal hyaline-like thick wall vessels, which revealed endarteritis obliterans and the fibrosis underlying this disease. These findings indicate that almagate enema is a novel effective, rapid and well-tolerated method for hemorrhagic CRP. Moderate to severe anemia is a risk factor for deep ulceration or fistula. Keywords: Chronic radiation proctitis - hemorrhage - almagate - risk factor - rectal fistula - enema. Asian Pac J Cancer Prev, 17 (2), 631-638 Introduction endoscopic argon plasma coagulation (APC) (Postgate et al., 2007), hyperbaric oxygen (Charneau et al., 1991), Radiation proctitis is a common complication after topical formalin application (Patel et al., 2009). Surgical radiotherapy for pelvic malignant tumors, for the fixed intervention is often reserved for refractory bleeding location of the rectum and anatomic relationship with or complications like fistula and stricture. And the other organs (Wang et al., 1998). Acute radiation-induced reported procedures included diversion colostomy and injury that occurred during radiotherapy is often self- proctectomy (Anseline et al., 1981; Khubchandani et al., limiting and easy-cured. The chronic modality that can be 1987; Lucarotti et al., 1991; Nowacki, 1991). The results delayed from months to years after radiation treatment, of these methods are variable and the overall efficacy has accounted for 5% to 20% of the cases (Pesee et al., been unsatisfactory (Kim et al., 2008). 2010). Chronic radiation proctitis (CRP) is difficult to This study was to introduce a novel agent of rectal manage for recurrent rectal bleeding and required blood almagate (aluminium-magnesium hydroxycarbonate transfusion in severe cases (Haas et al., 2007; Leiper and hydrate, an antacid agent) enema and evaluate its short- Morris, 2007; Patel et al., 2009). There are no well-defined and long-term efficacies for hemorrhagic CRP in our guidelines for the management of CRP. Various medical center. Furthermore, we performed analysis of potential agents for CRP have been reported , including sucralfate risk factors for rectal fistula in CRP patients. (Kochhar et al., 1988; R et al., 1991), 5-aminosalicylic acid analogue sulfasalazine (R et al., 1991), corticosteroids (R Materials and Methods et al., 1991), metronidazole (Eaveiæ, 2000), rebampide (Kim et al., 2008), short-chain fatty acid (Talley et al., Patients 1997), vitamin A (Patel et al., 2009) and pentoxifylline Patients with hemorrhagic CRP treated by (Hille et al., 2005). Other treatment modalities included hospitalization at the Sixth Affiliated Hospital of Sun 1Department of Colorectal Surgery, 3Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA &Equal contributors *For correspondence: Lei Wang ([email protected] or wangl9@mail. sysu.edu.cn), Jianping Wang ([email protected]) Asian Pacific Journal of Cancer Prevention, Vol 17, 2016 631 Zi-Xu Yuan et al Yat-Sen University were evaluated from 2007 to 2015. All social); three scales of symptoms (pain, fatigue, and patients underwent flexible colonoscopy before enema to nausea/vomiting); and one global health and quality of confirm the diagnosis of CRP. This study was approved life scale. Six single-item symptom measures (dyspnea, by the ethics committee of the Sixth Affiliated Hospital of insomnia, appetite loss, constipation, diarrhea, and Sun Yat-Sen University and was in accordance with the financial difficulties) were also included. provisions of the World Medical Association’s Declaration of Helsinki in 1995 (as revised in Tokyo 2004). Due to Risk factors the retrospective nature of the study, the informed consent Referring to the studies conducted by Li et al (Yang was waived. and Lv, 2012; Li et al., 2013), demographic and clinical variables which may affect the progression of CRP and Inclusion and exclusion criteria thus be possibly related to rectal deep ulcer or fistula CRP patients initially treated with rectal almagate (ulcer: ≥3 grades in VRS ) were evaluated: age; cumulative enema were enrolled. Patients with recurrent primary radiation dosage; presence of acute radiation-induced malignancies and had CRP less than 3 months after end enteritis; concomitant chemotherapy; latency of CRP; of pelvic radiation were excluded. These patients who duration of symptom; hypertension, diabetes mellitus were treated with almagate enema for less than one week and previous transfusion requirement; gynecological were also excluded. malignancy; CTCAE grades of bleeding; operations for primary tumors; body mass index (BMI); preoperative Grades and scores anemia; preoperative albumin and total protein in blood; Symptoms related to CRP, including rectal bleeding and APTT (activated partial thromboplastin time); and SCC other common concomitant symptoms such as anorectal (squamous cell carcinoma antigen) were also included in pain, tenesmus, stool frequencies, were graded before and the analysis of risk factors. after enema according to Common Terminology Criteria for Adverse Events (CTCAE) (CTCAE 4.0 – June 14, Statistical analysis 2010, National Institutes of Health). Typical endoscopic Statistical analysis was performed with SPSS version photos and pathological representative images were 13.0 software (IBM, USA). Continuous variables were collected to present the classical features of CRP. The analyzed by Student’s t test, and categorical variables were severity of endoscopic bleeding was scored according to compared by the Pearson Chi-square test. Parametric test - the endoscopic Vienna Rectoscopy Score (VRS) systems Wilcoxon rank sum test was performed to compare ranked (Wachter et al., 2000). Briefly, VRS contains five common data such as CTC grades of symptoms, VRS grades of endoscopic findings of CRP, i.e., telangiectasia, congested endoscopic findings, and the quality of life. Potential risk mucosa, ulceration, stricture, and necrosis. factors related to rectal fistula were evaluated by univariate analysis. Multivariate logistic regression analysis was not Almagate retention enema conducted because only one variable of moderate to severe Enemas were prepared by diluting 15 ml of almagate anemia with a P value less than 0.1. All P values were suspension (1.5 g) in 30-50ml normal saline. Almagate two-sided and less than 0.05 were considered statistically enemas were administrated through the anal via a soft significant. suction tube inserted 5-8cm into the anal verge twice daily at wards. Enemas were tried to retain in the rectum Results for about 60 min with intermittent position change from left lateral to supine and to right lateral every 20 minutes. Patients’ democraphics Since no previous experience of almagate enema existed, A total of fifty-nine patients treated for hemorrhagic patients were usually discharged upon the cessation or CRP at a single center were analyzed. Demographic and obvious reduction of rectal bleeding when it was possible clinical data were collected (Table 1). Gynecological and safe to continue enemas by self-administration at cancers composed 93.1% (55/59) of primary malignancies. home. Response was defined as a 0 or 1 grade of bleeding The mean radiation dosage was 82.5 Gy (range: 40-120 after enema. In those patients with poor response at Gy, defined as the cumulative dosage of external and 2 weeks, or requiring blood transfusion again were endocavitary radiation, and included the radiation for considered to be failed. both the site of primary malignancy and metastatic lymph nodes). The onset of symptoms occurred at a mean 9.3 Follow-up (range: 0-36) months after radiotherapy. Mean VRS was A long-term follow-up was done by a telephonic 3.9 points. questionnaire or by searching medical
Recommended publications
  • Par Drugs and Chemicals Limited
    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Floating Drug Delivery Systems Are Classified Depending on the Use of 2 Formulation Variables; 1
    Gastro Retentive Drug Delivery System (GRDDS) Drug absorption from the gastrointestinal tract is a complex procedure and is subject to many variables. ➢ the extent of gastrointestinal tract drug absorption is related to contact time with the small intestinal mucosa. ➢ Small intestinal transit time is an important parameter for drugs that are incompletely absorbed. ➢ Gastroretentive systems can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. ➢ Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility for drugs that are less soluble in a high pH environment. ➢ The controlled gastric retention of solid dosage forms may be achieved by the mechanisms of mucoadhesion, flotation, sedimentation, expansion, modified shape systems, or by the simultaneous administration of pharmacological agents that delay gastric emptying. Factors Affecting Gastric Retention The rate of gastric emptying depends mainly on viscosity, volume, and caloric content of meals. ➢ Increase in acidity and caloric value slows down gastric emptying time. ➢ Biological factors such as age, body mass index (BMI), gender, posture, and diseased states (diabetes, Chron’s disease) influence gastric emptying. ➢ In the case of elderly persons, gastric emptying is slowed down. ➢ Generally females have slower gastric emptying rates than males. ➢ Stress increases gastric emptying rates while depression slows it down. ➢ The resting volume of the stomach is 25 to 50 mL. Volume of liquids administered affects the gastric emptying time. When volume is large, the emptying is faster. ➢ Fluids taken at body temperature leave the stomach faster than colder or warmer fluids. ➢ Gastric emptying of a dosage form in the fed state can also be influenced by its size.
    [Show full text]
  • Comparative Study Among the Different Formulation of Antacid Tablets by Using Acid-Base Neutralization Reaction
    Global Journal of Pharmacology 9 (3): 278-281, 2015 ISSN 1992-0075 © IDOSI Publications, 2015 DOI: 10.5829/idosi.gjp.2015.9.3.95226 Comparative Study among the Different Formulation of Antacid Tablets by Using Acid-Base Neutralization Reaction 11Md. Jakaria, Rashaduz Zaman, 1Mohammad Parvez, 1Minhajul Islam, 21Md. Areeful Haque, Mohammed Abu Sayeed and 1Md. Hazrat Ali 1Department of Pharmacy, Faculty of Science and Engineering, International Islamic University Chittagong (IIUC), Chittagong 4203, Bangladesh 2Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia Abstract: Antacids were the mainstay of treatment for acid-peptic disorders until the advent of Hreceptor antagonist and proton pump inhibitors. We attempted to compare the activity of the different antacid tablets formulation by using acid-base neutralization reaction studies. This experiment based on acid-base neutralization reaction studies between independent variable (sample of antacid) and dependent variable (amount of acid needed to neutralize the antacid). The tablet code no. D neutralizes highest (7 ml) of acid solution and lowest (1.2 ml) was neutralizing by antacid code no. C. The sequences of antacid according to amount of acid required to neutralization was D> E> B> A> C. This in-vitro study may help in the deepest research works such as design and discovery of new antacid formulation. Key words: Antacids Acid Solution Neutralization In vitro INTRODUCTION aluminium hydroxide, aluminium phosphate, magnesium trisilicate, magnesium hydroxide, magnesium Antacids are commonly used world over as over the carbonate and calcium carbonate [5, 6]. The systemic counter (OTC) or prescribed medications.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Fdcs Permitted for Continued Manufacturing and Marketing in Respect of the Applicant Under 18 Months Policy Decision (As on 12.07.2018) Sr
    FDCs permitted for continued manufacturing and marketing in respect of the applicant under 18 months policy decision (As on 12.07.2018) Sr. No. Name of FDC Date of NOC 1 Dextromethorphan Hydrobromide IP 10mg+Phenylephirine HCl IP 5mg+Chlorpheniramine Maleate IP 2mg oral solution 16.09.15 2 Pantoprazole Sodium Sesquihydrate IP 40mg+Domperidone IP 10mg capsules 16.07.15 3 Pantoprazole Sodium IP 40mg+Domperidone IP 10mg tablets 16.07.15 4 Nimesulide BP 100mg+Paracetamol IP 325mg uncoated tablets 16.07.15 5 Ferrous Fumarate IP 150mg eq. to elemental Iron 48.75mg+L-Histidine HCl Monohydrate BP 4mg+L-Lysine HCl USP 16.07.15 25mg+Glycine IP 10mg+Riboflavin (Vit. B2) IP 3mg+Thiamine Mononitrate (Vit. B1) IP 5mg+Pyridoxine HCl IP (Vit. B6) 1.5mg+Cyanocobalamin (Vit. B12) IP 2.5mcg+Folic Acid IP 0.5mg capsules 6 Thiamine Mononitrate IP 5mg+Pyridoxine HCl IP 3mg+Cyanocobalamin IP 5mcg tablets 17.07.15 (NOC Withdrawn) 7 Ciprofloxacin 500mg+Tinidazole 600mg tablets 16.07.15 8 Cabonyl Iron 50mg+Folic Acid IP 0.5mg+Zinc Sulphate Monohydrate IP 61.8mg eq. to Zinc 22.5mg hard gelatin capsules 16.07.15 9 Calcium Phospahte 82mg+Vitamin D3 200IU+Vitamin B12 2.5mcg each 5ml suspension 17.07.15 10 Phenylephirine HCl 5mg+Chlorpheniramine Maleate 2mg per ml drops 17.07.15 11 Ferric Ammonium Citrate IP 160mg eq. toelemental Iron 32.8mg+Folic Acid IP 0.5mg+Cyanocobalamin IP 7.5mcg+Manganese 16.07.15 Sulphate IP 30mcg+Cupric Sulphate IP 30mcg per 15ml oral liquid 12 Dried Aluminium Hydroxide Gel IP 300mg+Magnesium Hydroxide Gel IP 250mg+Oxetacaine IP 10mg+Activated
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]